0001209191-22-008158.txt : 20220209
0001209191-22-008158.hdr.sgml : 20220209
20220209175250
ACCESSION NUMBER: 0001209191-22-008158
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220207
FILED AS OF DATE: 20220209
DATE AS OF CHANGE: 20220209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jiang Wenbin
CENTRAL INDEX KEY: 0001872873
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40632
FILM NUMBER: 22608576
MAIL ADDRESS:
STREET 1: C/O CYTEK BIOSCIENCES, INC.
STREET 2: 46107 LANDING PARKWAY
CITY: FREMONT
STATE: CA
ZIP: 94538
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cytek Biosciences, Inc.
CENTRAL INDEX KEY: 0001831915
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 472547526
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 47215 LAKEVIEW BOULEVARD
CITY: FREMONT
STATE: CA
ZIP: 94538
BUSINESS PHONE: (877) 922-9835
MAIL ADDRESS:
STREET 1: 47215 LAKEVIEW BOULEVARD
CITY: FREMONT
STATE: CA
ZIP: 94538
FORMER COMPANY:
FORMER CONFORMED NAME: Cytek BioSciences, Inc.
DATE OF NAME CHANGE: 20201110
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-07
0
0001831915
Cytek Biosciences, Inc.
CTKB
0001872873
Jiang Wenbin
C/O CYTEK BIOSCIENCES, INC.
47215 LAKEVIEW BOULEVARD
FREMONT
CA
94538
1
1
0
0
President and CEO
Common Stock
2021-12-04
5
G
0
E
5000
0.00
D
7842710
D
Common Stock
2022-02-07
4
S
0
20000
14.40
D
7889375
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Includes 66,665 shares received as a liquidation distribution from WYTJ LLC. In prior reports, the Reporting Person reported beneficial ownership of 2,666,600
shares of the Issuer's common stock held by WYTJ LLC.
/s/ Valerie Barnett, Attorney-in-Fact for Wenbin Jiang
2022-02-09